TriangleLurbinectedin (NCT07459634)
Lurbinectedin trial for Extensive-stage Small-cell Lung Cancer (NCT07459634). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with extensive-stage small-cell lung cancer that has not progressed after four platinum-and-etoposide chemotherapy cycles and at least three durvalumab cycles. Any history of brain metastases excludes participation.
The idea: continue with intravenous lurbinectedin plus durvalumab as maintenance. Lurbinectedin binds DNA; durvalumab blocks an immune brake. Researchers measure how many participants remain alive without progression at six months, and assess side effects.
This phase 2 study plans 50 patients. Jazz Pharmaceuticals sponsors it; five US sites are recruiting, including Los Angeles.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.